Compare Aurora Cannabis Inc (ACB) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

C.H. Robinson Worldwide (CHRW) trades at $149.35, up 1.83% on the day, with a bearish technical signal from moving averages but strong profitability metrics including a 37.12% ROE. Recent Q2 2026 earnings beat expectations with EPS of $1.61 versus $1.53 estimated, driven by pricing and efficiency gains. The stock shows support near $146 and resistance at $152, with a consensus analyst price target of $196.00 implying significant upside potential from current levels.

The outlook remains positive based on consistent earnings beats and solid fundamentals, though risks include soft freight demand and rising costs. Analyst sentiment is moderately bullish with 48% buy ratings, but investors should monitor competitive pressures and macroeconomic headwinds that could impact logistics sector performance.